In the realm of targeted therapies for lung cancer, the debate between Alectinib and Lorlatinib continues to stir discussions among oncologists and researchers. Alectinib, a drug approved for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), has been a game-changer in improving patient outcomes. Meanwhile, Lorlatinib, another ALK inhibitor, has...